Hair shedding during treatment is often due to telogen effluvium, a temporary shift in the hair growth cycle that can occur after major body changes
How often it happens The rates vary by trial and population: 2,3 TRIUMPH-4 (obesity with knee osteoarthritis): 8.8% on 9 mg, 20.9% on 12 mg, 0.7% on placebo TRANSCEND-T2D-1 (type 2 diabetes): 4.5% on 4 mg, 2.3% on 9 mg, 4.4% on 12 mg, 0% on placebo Phase 2 trial (Jastreboff 2023): not reported The TRIUMPH-4 numbers are markedly higher than those of TRANSCEND-T2D-1
Single-cell omics technologies Single-cell RNA sequencing (scRNA-seq) has become a key technology for studying female reproductive tissues, overcoming the fundamental limitation of bulk analysis that masks cellular heterogeneity [23, 24]
GLP-1 ineleri, farkl etki sresi ve kullanm zelliklerine sahip etken maddeler ierebilir
Assim como no tratamento do DM tipo 2, o custo costuma ser uma limitao para seu uso, alm dos efeitos adversos gastrointestinais
01 The GLP-1 Podcast Show is a new podcast created to spotlight the science, perspectives, and leaders shaping the future of obesity treatment and metabolic medicine